RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma
Drug Resistance Updates · 2025
DOI: 10.1016/j.drup.2025.101296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2025. Verfasst von Sifen Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center f…. Hauptthemen laut MEDLINE: Kelch-Like ECH-Associated Protein 1, NF-E2-Related Factor 2, Ferroptosis, Esophageal Squamous Cell Carcinoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Sun Yat-sen University Cancer Center, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Resistance to chemoradiotherapy is a crucial factor limiting the efficacy of therapy and prognosis of esophageal cancer. It is necessary to elucidate the key genes and regulatory mechanisms responsible for therapeutic resistance in esophageal squamous cell carcinoma (ESCC). In this study, we found a relationship between ferroptosis and therapeutic sensitivity in ESCC and identified the ring finger protein 217 (RNF217) as a new regulator of ferroptosis associated with resistance to chemoradiotherapy in ESCC. Mechanistically, RNF217 interacts with kelch like ECH associated protein 1 (KEAP1) and promotes its ubiquitination and degradation, resulting in nuclear factor erythroid 2-related factor 2 (NRF2) evading KEAP1-mediated degradation and, consequently, enhanced NRF2 signaling and led to ferroptosis resistance. Furthermore, NRF2 facilitated the transcription of RNF217 by binding to antioxidant response elements in the RNF217 promoter upon irradiation. Overall, our findings indicate that the RNF217-KEAP1-NRF2 feedback loop is a previously unrecognized mechanism regulating resistance to chemoradiotherapy in ESCC and could be a target to overcome therapeutic resistance in ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China; De…
- State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangdong Esophageal Cancer Institute, Guangzhou, China. El…
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Sun Yat-sen University Cancer Center
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Wang, S., Zhang, C., Zhou, S., Liu, S., Li, Q., Cheng, X., Wang, R., Chen, B., Li, Y., & Xi, M. (2025). RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2025.101296
Vancouver
Wang S, Zhang C, Zhou S, Liu S, Li Q, Cheng X, et al. RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma. Drug Resistance Updates. 2025. doi:10.1016/j.drup.2025.101296
BibTeX
@article{Wang2025,
author = {Wang, Sifen and Zhang, Chao and Zhou, Sha and Liu, Shiliang and Li, Qiaoqiao and Cheng, Xingyuan and Wang, Ruixi and Chen, Baoqing and Li, Yue and Xi, Mian},
title = {RNF217-KEAP1-NRF2 feedback loop confers therapeutic resistance by inhibiting ferroptosis in esophageal squamous cell carcinoma},
journal = {Drug Resistance Updates},
year = {2025},
doi = {10.1016/j.drup.2025.101296}
}
EUVIMED